SCHEMBL379598

SCHEMBL379598

NC(c1cccs1)c1nccc2scc(-c3ccc4c(c3)OCO4)c12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
CYP2D6 P10635 3/20 0.40
TSHR P16473 3/20 0.40
MAPK1 P28482 3/20 0.40
CYP2C19 P33261 3/20 0.40
CLK4 Q9HAZ1 3/20 0.40
CYP1A2 P05177 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
TP53 P04637 2/20 0.40
CYP3A4 P08684 1/20 0.40
HSD17B10 Q99714 4/20 0.39
ALOX15 P16050 3/20 0.39
CYP2C9 P11712 2/20 0.39
HPGD P15428 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
MAPT P10636 4/20 0.39
HTT P42858 2/20 0.39
CLK1 P49759 2/20 0.37
DYRK1A Q13627 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL380010 0.81 KDR (0.43) CLK4HSD17B10MAPTDYRK1ADYRK1B
SCHEMBL380530 0.80 KDR (0.43) ALDH1A1CLK4MEN1KMT2AMAPT
SCHEMBL379479 0.77 PKM (0.43) ALDH1A1CYP2D6TSHRMAPK1CYP2C19
SCHEMBL379851 0.75 MAPT (0.38) ALDH1A1TSHRHSD17B10HPGDMAPT
SCHEMBL379599 0.74 ALDH1A1 (0.63) ALDH1A1CYP2D6TSHRMAPK1CYP2C19
SCHEMBL2368448 0.69 HTT (0.47) ALDH1A1CYP2D6TSHRMAPK1CYP2C19
SCHEMBL379896 0.69 CLK4 (0.59) ALDH1A1CYP2D6TSHRMAPK1CYP2C19
SCHEMBL379615 0.66 CLK4 (0.53) ALDH1A1CYP2D6TSHRMAPK1CYP2C19
SCHEMBL379789 0.66 KDR (0.44) ALDH1A1TSHRCLK4TP53HSD17B10
SCHEMBL2369179 0.65 HTT (0.38) ALDH1A1CLK4MEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP claimed
EP-1968982-A2 THIENO (3,2-C) PYRIDINE COMPOUNDS Xention Discovery Ltd. (GB) 2008-09-17 EP claimed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US claimed
WO-2007066127-A2 THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS XENTION LIMITED (GB) 2007-06-14 WO claimed
US-9216992-B2 Thieno[3,2-c]pyridine potassium channel inhibitors XENTION LIMITED (GB) 2015-12-22 US disclosed
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP disclosed
EP-1968982-A2 THIENO (3,2-C) PYRIDINE COMPOUNDS Xention Discovery Ltd. (GB) 2008-09-17 EP disclosed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US disclosed
WO-2007066127-A2 THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS XENTION LIMITED (GB) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161672-A1 Compounds KCNJ2, KCNT1, KCNT2 ALDH1A1 371/4885CYP2D6 1169/4885TSHR 795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.